Merus N. V. , a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
Merus Nv stock last closed at $43.23, up 0.41% from the previous day, and has increased 6.87% in one year. It has overperformed other stocks in the Biotechnology industry by 0.84 percentage points. Merus Nv stock is currently +30.25% from its 52-week low of $33.19, and -29.83% from its 52-week high of $61.61.
At the moment, there are 69.09M shares of MRUS outstanding. The market value of MRUS is $2.99B. In the last 24 hours, 467,576 MRUS shares were traded.
How to Buy Merus Nv Stock
Wondering how to invest in Merus Nv stock? Here's how.
Figure out where to buy Merus Nv stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you determine where to buy Merus Nv stock.
Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Deposit funds into your brokerage account: Choose your method of payment and add your details.
Research Merus Nv stock: The Merus Nv ticker symbol is MRUS. Is Merus Nv stock a good investment? Should you buy shares of MRUS? How do MRUS's underlying business fundamentals look? Do top analysts think Merus Nv is a good buy? Why has MRUS's stock price moved recently? (Hint: Our stock research tools can help you evaluate if MRUS is a good stock to buy).
Place your MRUS purchase: Decide if you will purchase MRUS shares at the current market price or use a limit order to purchase MRUS shares at a particular price.
Get key alerts regarding your MRUS position: Create a watchlist to track your investment in Merus Nv shares.
Step 1: Figure out where to buy Merus Nv stock
You need a brokerage account to access the NASDAQ market and buy MRUS shares.
A brokerage account is an investment account that enables you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. eToro gives you:
Invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to global financial markets: From Tech to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've picked the best brokerage, it's time to fill out some personal info so you can invest in MRUS today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Merus Nv stock
Once you have decided on the best place to buy Merus Nv stock, it's crucial to research their stock before you invest, so you actually comprehend the risk as well as the opportunity.
Overview of key MRUS info
MRUS Price
$43.23
1w %
1.89%
1y %
6.87%
5y %
230%
P/E
-12.9x
P/B
4.61x
P/S
76.79x
PEG
N/A
Revenue
$36.13M
Earnings
-$215.33M
Fore. Rev. Growth
95.8%
Fore. Earn. Growth
N/A
Market Cap
$2.99B
Next Earnings
May 6, 2025
Next Dividend
N/A
Merus Nv Due Diligence Score
WallStreetZen was built to help everyday investors perform more accurate fundamental analysis quickly.
MRUS has cash burn of 187502000. It has sufficient cash and short-term investments to cover this for at least one year.
There are more short-term assets than short-term liabilities on the MRUS balance sheet.
There are more short-term assets than long-term liabilities on the MRUS balance sheet.
Total MRUS debt is lower than 5 years ago, relative to shareholder equity.
MRUS has a low debt to equity ratio of 0.21.
MRUS has $537.03M in cash and short term investments. This is enough to cover its annual cash burn of $187.50M.
Negative Health Checks:
MRUS profit margin has gone down from -352.6% to -595.9% in the past year.
Is MRUS stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 8 sell side analysts who give recommendations on MRUS, the consensus analyst rating on MRUS is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
Latest MRUS Analyst Recommendations
Yigal Nochomovitz, a top 15% analyst from Citigroup maintains MRUS with a strong buy rating and raises their MRUS price target from $89.00 to $97.00, on Dec 9, 2024.
Citigroup's Yigal Nochomovitz raised their price target on Merus Nv (NASDAQ: MRUS) by 9% from $89 to $97 on 2024/12/10. The analyst maintained their Strong Buy rating on the stock.
Nochomovitz attributed their price target hike on Merus NV to the petosemtamab monotherapy data in second-line and later head and neck squamous cell carcinoma that was recently presented at ESMO Asia.
The analyst explained that the "substantive" monotherapy data demonstrated about a 36% ORR as of the 2024/07/05 cutoff date and was largely consistent with prior cuts shared at AACR 2023.
Nochomovitz detailed that the new data "provides a significantly higher level of conviction" that 1500 mg is the right choice for both first-line and second-line Phase 3 work and that the monotherapy profile is now well-established from both an efficacy and safety perspective.
Richard Law, a top 21% analyst from Goldman Sachs initiates coverage on MRUS with a strong buy rating and announces their MRUS price target of $73.00, on Nov 21, 2024.
David Dai, a bottom 5% analyst from UBS initiates coverage on MRUS with a strong buy rating and announces their MRUS price target of $72.00, on Oct 24, 2024.
Last year, MRUS revenue was $36.13M. During the last 5 year, MRUS's revenue has increased by 3.02% per year. This was slower than the Biotechnology industry average of 44.31%.
No, Merus Nv doesn't provide an income stream by paying out dividends.
What do other traders have to say about MRUS?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your MRUS purchase
There are two primary order types:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are usually fine for most investors.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a specific dollar amount limit, place a limit order.
Click the Open Trade button and eToro will execute your order.
If you require additional help buying stocks on eToro, watch the helpful video below:
As of Apr 21, 2025, it costs $43.23 to buy one share of Merus Nv stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.231 shares of MRUS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.